Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14081583 | 0.71 | GAA (0.40) | — | |
| SCHEMBL13009901 | 0.70 | LMNA (0.37) | — | |
| SCHEMBL12149800 | 0.69 | KDM4E (0.32) | — | |
| SCHEMBL8744681 | 0.68 | CDK9 (0.32) | CDK9DYRK1ADYRK2 | |
| SCHEMBL21363701 | 0.68 | TRPA1 (0.30) | — | |
| SCHEMBL21721109 | 0.65 | ALDH1A1 (0.32) | CDK9DYRK1ADYRK2 | |
| SCHEMBL12109538 | 0.64 | RGS4 (0.36) | — | |
| SCHEMBL12251590 | 0.62 | — | — | |
| SCHEMBL16589269 | 0.61 | HSD17B10 (0.44) | — | |
| SCHEMBL1299013 | 0.59 | LMNA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415321-B2 | Nucleoside derivatives for treatment of Caliciviridae infections, including Norovirus infections | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2013-04-09 | — | — | US | disclosed |
| US-20090280084-A1 | NUCLEOSIDE DERIVATIVES FOR TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280084-A1 | NUCLEOSIDE DERIVATIVES FOR TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS | PNP, NUDT1, RNMT | CDK9 2261/4885DYRK1A 4311/4885DYRK2 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.